A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Cimaglermin alfa (Primary)
  • Indications Heart failure; Left ventricular dysfunction
  • Focus Adverse reactions; First in man
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 12 Mar 2018 Results assessing the safety and efficacy of cimaglermin presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 18 Mar 2017 Results (n=2) investigating cases of hepatotoxicity from two phase 1 trials (NCT01944683 and NCT01258387) meeting Hy's Law criteria, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 10 Mar 2015 According to an Acorda Therapeutics media release, data presented at the American College of Cardiology 64th Annual Scientific Session and Expo (ACC) 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top